ABO and Alzheimer disease: The observed glycosylation changes in AβO-activated hiMG have also been implicated in AD, as published data using brain or cerebrospinal fluid samples from participants with AD or mild cognitive impairment (MCI) highlighted altered levels of bisecting N-glycans, sialylation, and core fucose in N-glycans9,50–53.